Rare Disease Report

Why PFS is a Good Outcome Measure for Neuroendocrine Tumors

JUNE 05, 2015

Matthew Kulke, MD, of the Dana-Farber Cancer Institute explains why progressive free survival is a more appropriate outcome measure for clinical trials involving patients with neuroendocrine tumors.


Wolin Em, Caplin ME, Pavel ME, et al. Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).J Clin Oncol 33, 2015 (suppl; abstr e15180)

Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.